VIMOVO

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG

MAH:

ASTRA ZENECA ISRAEL LTD

ATC_code:

G02CC02

pharmaceutical_form:

TABLETS MODIFIED RELEASE

administration_route:

PER OS

manufactured_by:

ASTRA ZENECA AB., SWEDEN

therapeutic_group:

NAPROXEN

therapeutic_indication:

Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

authorization_date:

2011-12-01